HeyJaredDavid Brzostowicki
- Indexed articles, last 90 days
- 15
- Latest publication
- Sep 18, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 8, 2026
Latest articles
After 50 Years of Failed Attempts, Is a Drug Vaccine Close? (opens the original)
Read excerpt
In the early 1970s, a graduate student at Rockefeller University in New York City pitched an idea to his mentor, the physician who had given the world methadone maintenance: What if you could create a vaccine to train the immune system to intercept a drug before it reached the brain? The mentor, Vincent P. Dole, MD, was skeptical. Methadone already existed and was being used successfully. They also already had naloxone. Why would anyone choose a vaccine that took weeks to work over a pill that w
âGood First Tryâ: In Vivo CAR T for Neuro Autoimmune Disease (opens the original)
Read excerpt
A single intravenous infusion of an experimental therapy that trains the immune system to attack B cells involved in multiple sclerosis (MS) and other neurologic autoimmune disorders was associated with decreased disability and improvement in motor and cognitive function, a small early-stage trial showed. Called JY231, the therapy is an off-the-shelf lentiviral vector that directs the immune system to produce chimeric antigen receptor T cells (CAR T) directly in the body. While CAR T-cell therap
AI Digital Twins Get Better and Better: Cancer in Crosshairs (opens the original)
Read excerpt
Electrophysiologist Jonathan Chrispin, MD, wanted to do more. He was standing in the electrophysiology lab at Johns Hopkins University in Baltimore, catheter in hand, about to ablate a patient’s ventricular tachycardia (VT) — a potentially fatal arrhythmia caused by electrical circuits looping through scar tissue left behind by a heart attack. In a standard procedure, Chrispin would spend 5-8 hours mapping the scar point by point and burning through it with a 3.5 mm catheter tip. The success rat
Another Severe Chemo Shortage: Why Is the US So Vulnerable? (opens the original)
Read excerpt
There’s a conversation oncologists describe as one of the hardest in medicine, and it’s not about delivering a grim diagnosis. “There’s nothing more anguishing than looking at a patient and telling them that we know how to treat their cancer, and that the treatment is quite cheap — but we don’t have enough of it,” said Andrew G. Shuman, MD, a head and neck cancer surgeon and professor at the University of Michigan Medical School, Ann Arbor, Michigan. That conversation is now taking place at canc
Antiamyloidsâ Long-Term Cognitive Benefits Questioned (opens the original)
Read excerpt
Claims of increasing long-term benefit from lecanemab and donanemab are being called into question by a reanalysis of published data from the pivotal trials that led to the antiamyloids’ approval. Investigators found that cognitive decline was steeper during the drugs’ open-label extension (OLE) phases than during the preceding double-blind treatment periods and that the OLE decline rates were similar to those seen with placebo during the controlled trials. The investigators noted that the steep
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.